Basilea applies for Swiss clearance for ceftobiprole to treat foot infections |
|
|
|
Published
:
Thu, 23 Aug 2007 08:08
|
ZURICH (Thomson Financial) - Basilea Pharmaceutical AG said its partner Janssen-Cilag, a Johnson & Johnson company, has applied to Swiss medical watchdog Swissmedic for marketing authorisation for its ceftobiprole antibiotic in the treatment of diabetic foot infections.Swissmedic has already granted fast-track assessment of ceftobiprole for treating skin and soft tissue infections.Ceftobiprole is currently under review by regulatory authorities in the US, Canada and the EU.sarah.fenwick@thomson.comsf/jmsCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Basilea net loss widens to 64.4 mln sfr, just misses consensus UPDATE 